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Abstract
Background: The first week of human pre-embryo development is characterized by the induction
of totipotency and then pluripotency. The understanding of this delicate process will have far
reaching implication for in vitro fertilization and regenerative medicine. Human mature MII oocytes
and embryonic stem (ES) cells are both able to achieve the feat of cell reprogramming towards
pluripotency, either by somatic cell nuclear transfer or by cell fusion, respectively. Comparison of
the transcriptome of these two cell types may highlight genes that are involved in pluripotency
initiation.
Results: Based on a microarray compendium of 205 samples, we compared the gene expression
profile of mature MII oocytes and human ES cells (hESC) to that of somatic tissues. We identified
a common oocyte/hESC gene expression profile, which included a strong cell cycle signature, genes
associated with pluripotency such as LIN28 and TDGF1, a large chromatin remodelling network
(TOP2A, DNMT3B, JARID2, SMARCA5, CBX1, CBX5), 18 different zinc finger transcription factors,
including  ZNF84, and several still poorly annotated genes such as KLHL7,  MRS2, or the
Selenophosphate synthetase 1 (SEPHS1). Interestingly, a large set of genes was also found to code
for proteins involved in the ubiquitination and proteasome pathway. Upon hESC differentiation into
embryoid bodies, the transcription of this pathway declined. In vitro, we observed a selective
sensitivity of hESC to the inhibition of the activity of the proteasome.
Conclusion: These results shed light on the gene networks that are concurrently overexpressed
by the two human cell types with somatic cell reprogramming properties.
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Background
Oocytes have the unique ability to remodel the chromatin
of the germinal nuclei into a totipotent state. These mod-
ifications are particularly striking for the male pro-nuclei:
upon fertilization, the sperm chromatin packaging pro-
tamines are stripped off and replaced by histones, the
DNA is demethylated within 4 hours of fertilization, and
the amino terminal tails of histones are modified includ-
ing methylation of arginin 9 and phosphorylation of serin
10 of histone H3 (H3K9 and PhH3S10, respectively) [1,2].
Remarkably, the reprogramming properties of oocytes are
not restricted to the very specialized germinal nuclei.
Indisputably, the cloning of Dolly has shown that the
oocyte cytoplasm is able to extensively reverse the chro-
matin modifications associated with a differentiated state
[3,4]. Somatic cell nuclear transplantation (SCNT) has
since been extended to other species, including human
cells, and to many cell types, including terminally differ-
entiated cells such as granulocytes [5,6]. Thus differentia-
tion is not anymore considered as an irreversible process,
but rather as modifications of the cellular epigenome and
transcriptome, that are amenable to complete reversal. In
addition to oocytes, other cell types can reprogram
somatic cells towards pluripotency. For example, using
cell fusion strategies, it has been shown that hybrid cell
clones obtained by fusion of a differentiated cell with
either teratocarcinoma cells or embryonic stem cells dis-
play features of pluripotent, undifferentiated cells with
concomitant loss of the markers associated with differen-
tiation [7,8]. More recently, and quite unexpectedly, Taka-
hashi and Yamanaka have shown that the expression of
only four selected transcription factors, OCT3/4, SOX2,
CMYC and KLF4, is sufficient to drive a mouse fibroblast
into an induced pluripotent stem cell (iPS) with all the
features of embryonic stem cells, including a high growth
rate and the ability to form a variety of tissues from all
three germ layers in vitro and in vivo [9]. These results
have been confirmed by other studies, extended to human
cells, and applied to non-fibroblastic cells such as mesen-
chymal stem cells (MSCs), gastric epithelial cells or hepa-
tocytes [10-12]. At the center of cellular reprogramming
lies the activation of the pluripotency transcriptional reg-
ulatory circuitry involving POU5F1/OCT4, NANOG and
SOX2 [13] and extensive chromatin-remodeling. How-
ever, the details of this process, such as the exact media-
tors of the chromatin modifications, remain ill defined.
Data from xenopus egg experiments point to nucleosomal
ATPases, but these findings await confirmation using
mammalian oocytes [14,15].
As oocytes and ES cells are two cell types able to repro-
gram a somatic cell such as fibroblasts into pluripotent
cells, the comparison of the gene expression program of
these two cell types could contribute to the understanding
of these cell reprogramming properties. Therefore, we
generated a transcriptome compendium of 205 samples
by collecting public microarray data and compared the
gene expression profile of oocytes and hESC to that of
somatic tissues. We defined a common oocyte/hESC sig-
nature, which comprised many cell cycle genes, but also
several biological pathways not associated with cell
growth. Strikingly, a large set of genes is coding for genes
involved in protein ubiquitination and the proteasome
pathway. Upon hESC differentiation into embryoid bod-
ies, the transcription of this pathway declines. In agree-
ment with this preferential expression in pluripotent cells,
we observed a selective sensitivity of hESC to the pharma-
cological inhibition of the proteasome activity, suggesting
a role for this machinery in the maintenance of pluripo-
tency.
Results
Human oocytes and hESC share a common transcriptome 
signature
To identify a gene expression signature shared by mature
oocytes and hESC but not by somatic cells, we confronted
9 oocyte and 29 hESC expression profiles to a transcrip-
tome collection of 167 samples spanning a wide variety of
fetal and adult somatic cell samples (see Table 1; see Addi-
tional file 1). This microarray compendium quantified the
expression of 13 279 unique Refseq transcripts in a total
of 205 samples (see Methods and Additional file 2). A
non-supervised analysis using principal component anal-
ysis (PCA) mapped the samples in a two dimensional
space with a differentiation gradient ranging from undif-
ferentiated hESC samples to highly specialized tissues
such as hematopoietic cell samples or nervous system tis-
sue samples (Figure 1A). The hESC samples grouped
together very tightly, even though the transcriptomes were
obtained from six different studies and included 15 differ-
ent hESC cell lines, in agreement with the low variation
between hESC cell lines [16] and the robustness of the
Affymetrix microarrays [17]. Strikingly, the human
mature oocyte samples were situated in the vicinity of the
hESC samples, distantly located from most somatic tis-
sues samples. A hierarchical clustering confirmed these
findings, showing that MII oocytes and hESC clustered
together, sharing a signature of overexpressed genes, dem-
onstrating a close gene expression (Figure 1B; see Addi-
tional file 3). We computed an oocyte and a hESC
signature by comparing each of these two categories to
somatic cells. Using Significance Analysis of Microarrays
(SAM) software with a false discovery rated (FDR) of
0.05% and a ratio between groups of at least 2, we deter-
mined that oocytes overexpressed 2622 probesets (PS)
(2097 different Refseq transcripts) compared to somatic
samples, whereas hESC overexpressed 1792 PS (1436 dif-
ferent Refseq transcripts) (see Additional file 4). The
"oocytes signature" comprised DAZL, SOX30, ZP2, GDF9,
AURKC, PTTG3, etc. (Figure 1C) which have previouslyBMC Genomics 2009, 10:10 http://www.biomedcentral.com/1471-2164/10/10
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Table 1: Samples of the microarray compendium
Cell type Tissue or cell line Normal or Malignant Number of samples References
Normal cell compendium (n = 205)
Human embryonic stem cells Cell line Normal 29 [38-43]
Mature oocytes Cells Normal 9 [18,44,45] and this study
Foreskin fibroblasts Cell line Normal 4 [40]
Ovary Tissue Normal 3 [46,47]
Central nervous system Tissue Normal 44 [46,47]
Peripheral nervous system Tissue Normal 18 [46,47]
Skin and keratinocytes Tissue and cultured primary cells Normal 6 [39]
Lung Tissue Normal 11 [46,47]
Digestive tract Tissue Normal 19 [46,47]
Thyroid Tissue Normal 5 [46,47]
Adipocytes Tissue Normal 2 [46,47]
Kidney and prostate Tissue Normal 6 [46,47]
Heart and muscle Tissue Normal 10 [46,47]
Hematopoietic tissues Tissue and purified cells Normal 30 [39,46,47]
Uterus Tissue Normal 6 [46,47]
Placenta Tissue Normal 3 [46,47]
Highly cycling cells compendium (n = 22)
Leukemia cell lines Cell line Malignant 8 [47]
Lymphoma cell lines Cell line Malignant 4 [47]
Early erythroid cells Cultured primary cells Normal 2 [47]
Endothelial cells Cultured primary cells Normal 2 [47]
Hepatocarcinoma cell line Cell line Malignant 2 This study
Colorectal cancer cell line Cell line Malignant 2 [47]
Breast cancer cell line Cell line Malignant 2 This study
A summary of the microarray samples used in this study (A full list of samples is found in Additional file 1)BMC Genomics 2009, 10:10 http://www.biomedcentral.com/1471-2164/10/10
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been identified as overexpressed by female germinal cells
by our group and others [18,19]. Similarly, the "hESC sig-
nature" displayed numerous genes known to be specifi-
cally overexpressed in hESC such as POU5F1/OCT4,
NANOG,  DPPA4,  TDGF1,  CD24,  PODXL,  HELLS, etc.
[20]. These findings validated the biological relevance of
our compendium and the signatures specific to oocytes
and hESC. We intersected these two lists of genes and
established a "oocyte/hESC signature", composed of 652
PS (558 different Refseq transcripts) (Figures 1D; see
Additional file 4).
A strong cell cycle signature
To get an insight into the oocyte/hESC signature, we
searched for overrepresented gene ontology (GO) func-
tional annotations. As expected from our previous studies
on oocytes transcriptome or hESC transcriptome [18,20],
the oocytes/hESC signature was highly enriched in genes
associated with intra-cellular localization, DNA and RNA
binding, and conversely, it was significantly depleted in
genes which encode for secreted proteins or proteins
implicated in signal transduction (Figure 2A and 2B).
Remarkably, we observed that the biological process
Human mature MII oocytes and hESC display a common transcriptome signature Figure 1
Human mature MII oocytes and hESC display a common transcriptome signature. Principal component analysis 
(PCA) (A). A PCA of 9 mature oocytes (MII), 29 hESCs and 167 somatic tissue samples. CNS, central nervous system; PNS, 
peripheral nervous system. Hierarchical clustering (B). Each horizontal line represents a PS and each column represents a single 
sample. PS up and down-regulated were colored in red and purple, respectively. In white, PS which were neither over nor 
under-expressed. Clusters: a: hESCs genes; b: MII oocytes genes; c: the oocytes/hESC signature; d: genes expressed in CNS; e: 
genes expressed in hematopoietic cells. AD: adipocytes; hFF: human foreskin fibroblasts; SK: skin and keratinocytes; DT: diges-
tive tract; Hemato: hematopoietic cells; PL: placenta; H: heart; LU: lung; TH: thyroid; UT: uterus; OV: ovary; M: muscle. 
Expression bar charts of selected genes (C). Expression bar charts of three oocytes specific genes (DAZL, SOX30, ZP2), three 
hESCs specific genes (POU5F1/OCT4, NANOG, and DPPA4), three genes up-regulated in hESC and oocytes MII (DNMT3B, TOP2A 
and ZNF84) and one ubiquitously expressed gene (RPL4) using our on-line expression atlas Amazonia! http://amazo-
nia.montp.inserm.fr. Diff: non-specific differentiated hESC; MCF7: breast cancer cell line; HEPG2: hepatocarcinoma cell line. 
Venn diagram detailing shared and distinct gene expression among hESCs and MII human oocytes (D). The oocyte/hESC signa-
ture was defined as the intersection of the hESC signature (genes overexpressed in hESC compared to somatic tissues (ST)) 
and the MII oocytes signature (genes overexpressed in MII oocytes compared to ST). The oocytes/hESC signature was then 
further parted into a fraction sharing a cell cycle signature and a non-cell cycle part.BMC Genomics 2009, 10:10 http://www.biomedcentral.com/1471-2164/10/10
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annotations related to cell cycle such as "mitotic cell
cycle", "cell cycle progress", "nucleobase, nucleoside,
nucleotide synthesis" were among the most highly
enriched in the oocyte/hESC signature (P < 1. 10-3). These
findings were in line with the very short cell cycle duration
of primate ESC [21] and with the fact that MII oocytes
samples are pure populations of cells undergoing the sec-
ond meiotic division, which has many features of mitosis.
Thus, these two tissue types highly express genes involved
in the process of cell division. To delineate more clearly
the cell cycle contribution to the oocyte/hESC signature,
we defined a cell cycle signature independently from the
oocytes and hESC samples. We compared samples charac-
terized by a high proliferation index to our somatic sam-
ples series. Proliferating samples included normal cells
such as rapidly dividing CD71+ early erythroid progeni-
tors and CD105+ endothelial cells, as well as cell lines
originating from haematological, hepatic, breast and
colorectal tumors (See Table 1 and Additional file 1 for
the list of additional samples). A SAM analysis with a FDR
Biological annotations of genes overexpressed in human mature MII oocytes and hESC Figure 2
Biological annotations of genes overexpressed in human mature MII oocytes and hESC. Cellular compartment 
localisation according to Gene Ontology (GO) annotations (A). Statistical comparison of the distribution of GO annotations in 
the oocytes/hESC signature with the genes underexpressed in oocytes and hESC (B). Gene Ontology categories which differed 
significantly (p value ≤ 0.01) between oocytes and hESC are shown. Oocyte/hESC gene networks (C). We computed interac-
tion networks from the oocyte/hESC signature. Genes included in the oocyte/hESC signature are in red (the color intensity is 
proportional to the oocyte/hESC to somatic samples fold change). Genes not found in the signature are in white. In each net-
work, edge types are indicatives: a plain line indicates direct interaction, a dashed line indicates indirect interaction; a line with-
out arrowhead indicates binding only; a line with an arrowhead indicates "acts on". Node types represent different types of 
molecules: diamond, enzyme; square, cytokine; triangle, phosphatase; and circle, other. Double line edge represents a group or 
a complex. Validation of microarray data (D). Gene expression of DNMT3A, SMARCA5, PSMA5, PSMA2 were assayed with 
quantitative RT-PCR (QRT-PCR). The expression of these four selected genes was compared in mature oocytes, hESC and 
various somatic samples: human fibroblasts (hFF), human breast adenocarcinoma cell line (MCF7), human hepatocellular liver 
carcinoma cell line (HepG2), endometrial cells (End7) and T-lymphocyte cells (TL) using QRT-PCR. All measurements were 
performed in duplicate in two separate runs. The relative levels of gene expression of target mRNA was normalized against 
GAPDH expression. Fold change values are plotted on a log10 scale.BMC Genomics 2009, 10:10 http://www.biomedcentral.com/1471-2164/10/10
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of 0.05% identified 818 PS (682 different Refseq tran-
scripts) overexpressed in proliferating somatic samples,
composing a "cell cycle signature". Intersection with the
oocyte/hESC signatures revealed that 220 PS (33.7%)
were shared with the cell cycle signature (Figure 1D; see
Additional file 4). This cell cycle part of the oocytes/hESC
signature included enzymes involved in general cell
metabolism (METAP2, SHMT2, etc.), nucleoside synthe-
sis (DHFR, TYMS, RRM2, PPAT, etc.), DNA repair includ-
ing mismatch repair (MSH2 and MSH6) or base excision
repair (UNG, PCNA), main components of the cell cycle
regulatory machinery (CCNB1 and 2, CCNA, CCNE, etc.),
regulator of the topologic state of DNA (TOP1, TOP2A)
and components of the mitotic spindle assembly check-
point (the centromer constituents CENPE, the securin
PTTG1, and MAD2L1, BUB1B, BUB3) (Figure 2C). How-
ever, it must be noted that 36 genes from the oocyte/hESC
signature that are functionally annotated "cell cycle" by
Gene Ontology were not included in the cell cycle signa-
ture. These are cell cycle genes that are preferentially
expressed in mature oocytes and hESC as compared to
other cycling cell types such as malignant cell lines or pro-
liferating primary hematopoietic cells, and included the
spindle checkpoint gene CHEK1, FBXO5/EMI1, the cyclin
dependent kinase-activating kinase CDK7 and a compo-
nent of transcription factor IIH, CDK8.
Human oocytes and hESC share a large chromatin 
remodelling network
We focused the second part of our analysis on the non-cell
cycle part of the oocyte/hESC signature. Removing the
220 cell cycles PS led to the definition of a "non-cell cycle
oocyte/hESC signature" that retained 432 PS (384 tran-
scripts). This signature contained many transcripts
involved in DNA and histone modifications. One of these
transcripts was DNMT3B, involved in DNA methylation.
The high fold change of DNMT3B in hESC and oocytes
compared to somatic samples (43.4 and 9.4, respectively)
suggests a central role of this DNA methyltransferase in
the control of the epigenome of these cells. In addition,
several transcripts, comprising JARID2, SMARCA5, CBX5,
CHAF1A and CBX1, were involved in histone modifica-
tion processes (Figure 2C). We selected two chromatin
remodelling genes, DNMT3B  and  SMARCA5, and vali-
dated by QRT-PCR their preferential expression in oocytes
and hESC compared to somatic samples (Figure 2D).
Zinc finger genes
Mature MII oocytes and hESC overexpressed numerous
zinc finger domain genes. The zinc finger motif is a DNA
binding domain dependent on a zinc ion, frequently
found in transcription factors. The non-cell cycle oocyte/
hESC signature was significantly enriched in zinc finger PS
: 20 (18 Refseq transcripts) out of 432 PS (4.6%) in the
signature compared to 611 out of 22215 PS (2.7%) in the
complete list of PS (P = 0.018) (Table 2). The expression
bar charts for the zinc finger domain gene ZNF84 is
shown in Figure 1C and that of all 18 zinc finger domain
genes from the non-cell cycle oocyte/hESC list is available
as Additional file 5.
Ubiquitination and proteasome
Surprisingly, we found that a highly significant propor-
tion of genes of the non-cycle oocytes/hESC signature was
involved in the protein ubiquitination and proteasome
canonical pathway (P-value ≤ 1.93E-06, using Ingenuity
software) (Figure 3A). Enzymes from the three E1/E2/E3
ubiquitination classes were found significantly overex-
pressed in the functional regulatory network: the E1 ubiq-
uitin-activating enzyme UBE1C, the E2 ubiquitin-
conjugating enzymes UBE2G1, UBE2V1 and UBE2V2, and
the E3 ubiquitin protein ligases UBE3B and breast cancer
1, early onset (BRCA1) (Figure 3A). It was recently showed
that BRCA1 is part of a holoenzyme complex containing
BRCA1, BRCA2, BARD1 and RAD51 which is called the
BRCA1- and BRCA2-containing complex (BRCC) that dis-
plays an ubiquitin E3 ligase activity [22]. We found that
three out of the four components of BRCC, namely
BARD1,  BRCA1  and  RAD51  are overexpressed in MII
oocytes and hESC whereas BRCA2 is simply expressed.
One key consequence of protein ubiquitination is to tar-
get proteins for degradation by the 26S proteasome. In
line with the biased high expression of ubiquitination
pathway components, we also found many subunits of
the proteasome significantly overexpressed in MII oocytes
and hESC (Figure 3B). As expected for a ubiquitous cell
machinery complex, the expression of most subunits of
the 26S proteasome is detected by microarrays in oocytes
and hESC. Among these, four catalytic alpha proteasome
subunits (PSMA2, PSMA3, PSMA4 and PSMA5) and three
regulatory subunits, the ATPase PSMC6  and the non-
ATPase PSMD10 and PSMD11, are significantly upregu-
lated in MII oocytes and hESC as compared to somatic tis-
sues (P < 0.001 for each cited proteasome subunit) (Figure
3B), in line with the overexpression of the ubiquitin path-
way. In addition, three ubiquitin-specific proteases
(USP1,  USP7  and  USP9X), that are deubiquitinating
enzymes, were also found highly expressed in the oocytes
and hESC. Remarkably, microarray analysis showed that
upon differentiation, the expression level of proteasome
components that are overexpressed in hESC decreased to
a level similar to that of somatic cells (Figure 3C).
High sensitivity of human embryonic stem cells to 
proteasome inhibition
The high expression level of the proteasome machinery in
hESC and its decrease during hESC differentiation sug-
gested that this pathway could play an important role in
pluripotent cells. To determine the consequence of func-
tional blocking of the proteasome activity in hESC, weBMC Genomics 2009, 10:10 http://www.biomedcentral.com/1471-2164/10/10
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tested the effect of MG132, a specific proteasome inhibi-
tor, on embryonic stem cells [23]. Increasing doses of
MG132 were added to the culture media of HS181 hES
cells. At 250 nM the morphology of the hESC colonies
clearly showed large patches of differentiation and at 500
nM no undifferentiated cells remained (Figure 4A). Fur-
thermore, when colonies contained mixed populations of
undifferentiated and differentiated cells, 1 μM of MG132
induced the detachment of the undifferentiated cells
whereas the differentiated progeny stayed tightly sticked
to the dish. These results were reproduced on two other
hES cell lines (HD83 and HD90, data not shown). By con-
trast, the morphology and adhesion of human foreskin
fibroblasts (HFF) were not altered by MG132 at concen-
Table 2: Genes from the mature oocyte/hESC signature with a Zinc finger domain.
Gene Symbol Probe Set Gene Title Chromosomal 
Location
Fold change Oocyte 
MII (a)
Fold change hESC (b)
DPF2 202116_at D4, zinc and double PHD 
fingers family 2
chr11q13 6.1 2.1
GATAD2A 218131_s_at GATA zinc finger domain 
containing 2A
chr19p13.11 9.8 2.8
LOC730051 221963_x_at Similar to Zinc finger 
protein 418
chr19q13.43 5.9 2.5
RCHY1 214281_s_at ring finger and CHY zinc 
finger domain containing 1
chr4q21.1 5.7 3.3
ZC3H13 212402_at zinc finger CCCH-type 
containing 13
chr13q14.12 3.2 2.4
ZC3H15 201595_s_at zinc finger CCCH-type 
containing 15
chr2q32.1 3.5 2.3
ZCCHC8 218478_s_at zinc finger, CCHC domain 
containing 8
chr12q24.31 4.5 2.6
ZFAND6 221613_s_at zinc finger, AN1-type 
domain 6
chr15q25.1 13.8 3.1
ZMYM2 202778_s_at zinc finger, MYM-type 2 chr13q11-q12 33.1 3.4
ZNF131 221842_s_at zinc finger protein 131 chr5p12-p11 8.8 2.2
ZNF281 218401_s_at zinc finger protein 281 chr1q32.1 6.5 3.1
ZNF3 212684_at zinc finger protein 3 chr7q22.1 2.8 2.1
ZNF330 209814_at zinc finger protein 330 chr4q31.1-q31.2 3.5 2.4
ZNF508 203322_at zinc finger protein 508 chr18q23 4.5 3.9
ZNF588 205739_x_at zinc finger protein 588 chr7q11.2 6.4 2.1
ZNF84 204453_at zinc finger protein 84 chr12q24.33 3.1 2.5
ZNF93 215758_x_at zinc finger protein 93 chr19p12 10.3 2.1
ZZZ3 212893_at zinc finger, ZZ-type 
containing 3
chr1p31.1 2.1 2.2
List of genes from the oocyte/hESC signature that display a zinc finger domain, with PS number, and fold change (oocyte versus somatic tissues (a) 
and hESC versus somatic tissues (b).BMC Genomics 2009, 10:10 http://www.biomedcentral.com/1471-2164/10/10
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tration up to 1 μM (Figure 4B). Moreover, we differenti-
ated the HD90 and HS181 hESC into hES-differentiated
fibroblasts (dF) that display features characteristic of
fibroblasts: flattened cells with elongated nucleus and
branching pseudopodia, expression of membrane mark-
ers such as P4H, CD13 or CD44. Treatment with MG132
did not induce changes in cell morphology of the hES-dF-
HD90 (Figure 4C) and hES-dF-HS181 (data not shown),
even at high concentrations. RT-PCR analysis showed that
expression of pluripotency markers decreased when hESC
were treated with MG132. Whereas the expression of
POU5F1/OCT4, SOX2 and NANOG decreased with the
proteasome treatment, GAPDH expression was not modi-
fied (Figure 4D). This effect was also substantiated by flow
cytometry. We observed decreasing expression of the
pluripotency marker TRA-1-60 on HS181 hESC after
exposition to MG132 (Figure 4E). However, high concen-
tration of MG132, up to 1 μM, did not affect two different
fibroblasts cell surface markers, CD44 and CD13 on hFF,
on hES-dF-HS181 or on hES-dF-HD90. Thus, our results
showed that pluripotent hESC are highly susceptible to
the action of proteasome blockage, whereas somatic cells
Overexpression of the ubiquitination/proteasome pathway Figure 3
Overexpression of the ubiquitination/proteasome pathway. Interaction network analysis of the ubiquitination/proteas-
ome pathway in the oocytes/hESC signature. (A) The interaction network was generated with the Ingenuity software and 
shows a high number of genes from this cellular pathway overexpressed (red) or expressed (orange) in the oocytes/hESC sig-
nature. Transcripts that were not detected by the microarray are white. Notably, we found elements of the ubiquitin-activating 
enzyme (UBE), BRCA1- and BRCA2-containing complex (BRCC), the regulatory 19S proteasome, the core proteolytic 20S 
proteasome and the ubiquitin-specific protease (USP) modules in the oocyte/hESC signature. Gene expression measured by 
microarrays in 9 genes involved in the ubiquitin and proteasome pathway (B). Box-and-whisker plots comparing the expression 
level of PSMA2, PSMA3, PSMA4, PSMA5, PSMC6, PSMD10, PSMD11, UBE2G1 and SKP2 in mature oocytes and hESC (38 samples) 
versus somatic tissues (167 samples). The signal intensity for each gene is shown on the y axis as arbitrary units determined by 
the GCOS 1.2 software (Affymetrix). (*): P-value < 0.0001 using a Mann-Whitney statistical test. Down regulation of the pro-
teasome pathway during hESC differentiation (C). U133A microarray signal values for PSMA2, PSMA4 and PSMA5 in 29 undiffer-
entiated hESC samples (mean value) versus two embryoid bodies (EB) samples (EB day 5 and EB day 14) and 3 non-lineage 
differentiated hESC samples (mean value).BMC Genomics 2009, 10:10 http://www.biomedcentral.com/1471-2164/10/10
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such as hFF or the differentiated progeny of hESC such as
hES-dF were not affected.
Discussion
Early human embryo development results in the repro-
gramming of highly specialized germinal cells into totipo-
tent and then pluripotent cells that are the progenitors of
all the specialized cell types of the human body. This
unique biological property has been harnessed to restore
pluripotency in human somatic cells by SCNT or cell-
fusion using embryonic stem cells [6,7]. hESC share with
pluripotent stem cells from the inner cell mass pluripo-
Blocking proteasome activity in hESC Figure 4
Blocking proteasome activity in hESC. Proteasome inhibition causes differentiation of hESCs (A). HS181 colonies (p56) 
were grown 4 days on hFF and then treated 40 hours with the proteasome inhibitor MG132. Control HS181 colonies express 
POU5F1 (scale bar 25 μ) and display a normal karyotype. Upon treatment with MG132, HS181 colonies differentiated. No 
effect of proteasome inhibition on hFF (B). HFF express the fibroblastic marker P4H and display a normal karyotype. HFF were 
cultured with MG132 during 40 hours. No morphological alteration was observed. No effect of proteasome inhibition on hES-
dF-HD90 (C). The HD90 hESC line was differentiated into fibroblasts like cells (hES-dF) that display morphologic feature of 
dermal fibroblasts and express P4H: bottom left. An undifferentiated colony of HD90 P4H-, starts to differentiate at the edges 
into P4H+ hES-dF (upper left). hES-dF-HD90 cells were cultured with MG132 during 40 hours. No morphological alteration 
was observed. Down regulation of pluripotency transcription factor in hESC by proteasome blockage (D). The expression of 
POU5F1/OCT4, NANOG and SOX2 was measured by semiquantitative RT-PCR in HS181 hESC after 40 h culture with 
MG132. GAPDH was used as a control. Flow cytometry analysis after proteasome inhibition (E). HFF, hES-dF-HS181 and 
HS181 cells were treated 40 hours with MG132, and then the cell surface fibroblastic markers CD13 and CD44, and the 
pluripotent cell surface marker TRA-1-60 were measured by FACS. Markers for fibroblastic cells were not altered with 
MG132 treatment, whereas the marker for pluripotency dropped to barely detectable level. Y-axis: percentage of the control 
(untreated) sample.BMC Genomics 2009, 10:10 http://www.biomedcentral.com/1471-2164/10/10
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tency transcription factors and multi-lineage differentia-
tion properties, and are considered a good in vitro model
for pre-embryo pluripotent stem cells. Though human
oocytes and ESC are developmentally separated by less
than one week, the transcriptome of the oocyte undergoes
rapid changes after fertilization [24,25]. We undertook to
find out a common expression signature to these two cell
types, that share somatic cell reprogramming properties,
by comparing them to a large collection of somatic tissues
samples. A first observation was that the oocytes/hESC
signature was highly enriched in genes involved in cell
cycle. Whereas this was expected because of the cell cycle
status of these two cell types, the expression of a large set
of genes associated with cell division is nevertheless of
interest for cellular reprogramming. As recently reported,
prior mitotic remodeling of the somatic nuclei, involving
topoisomerase II (TOP2)-dependent shortening of chro-
matin loop domains and an increased recruitment of rep-
lication initiation factors onto chromatin, is essential for
reprogramming of differentiated nuclei [26]. Strikingly,
we found that TOP2A was highly up-regulated in both
oocytes and hESC. This observation suggests that TOP2A
could be a major factor in the reprogramming properties
of oocytes and hESC by participating in chromatin
remodeling. Conversely, the identification of a "cell cycle
signature", shared with highly proliferating tissues such as
cancer cell lines, provided a mean to identify by subtrac-
tion a "non-cycle oocytes/hESC" signature of 432 PS. This
signature included transcripts coding for proteins
involved in chromatin structure modifications such as
DNMT3B, JARID2, SMARCA5 or CBX5 that contribute to
the DNA methylation and chromatin remodeling (Figure
2C). Consistent with these observations, hESC display a
distinct, permissive, chromatin structure compared with
other tissues [27]. Expression of DNA methyl-transferases
or several ATP-dependent chromatin remodelling factors
are elevated in murine oocytes or ES cells [28,29]. Thus
our findings show large similarities between murine and
human ES cells, and put forward several genes whose
strong overexpression could contribute to the specific
chromatin state of hESC.
Another lesson from our transcriptomic approach is that
the common oocytes/hESC gene expression profile has a
very low number of genes that are either secreted or mem-
brane bound (Figure 2A). This is in line with our previ-
ously published data that booth oocytes and hESC
"specific genes" are significantly depleted in extracellular
signalling components, suggesting that this feature is
indeed a common characteristic shared by oocytes and
hESC and is not simply due to a lack of overlap [18,20].
Hence, genes specifically shared by oocytes and hESC are
largely nuclear proteins. One assumption that can be
inferred from these findings is that determinant of
pluripotency may be mostly intrinsic factors. This obser-
vation converges on a recent model, which proposed that
pluripotency is a ground state that is intrinsically self-
maintained when protected from extrinsic differentiation
stimuli [30].
An unexpected observation was that genes involved in
protein ubiquitination and proteasome pathway were
also overrepresented in the oocytes/hESC signature. This
could be linked to the strong proliferation signature of
hESC and oocytes as this pathway is by many way impli-
cated in the regulating the cell cycle [31]. However, the
overexpression of the ubiquitination/proteasome path-
way was still significant when the cell cycle signature was
substracted, suggesting that this pathway could have a role
in pluripotent cells in addition to its house keeping or cell
cycle functions. In line with these results, we showed a
selective sensitivity of hESC to the inhibition of the activ-
ity of the proteasome, resulting in loss of pluripotency
and cell growth at doses without any detectable effects on
differentiated but cycling cells such as primary fibroblasts
or hESC derived fibroblast like cells. In addition, it must
be stressed that the dramatic effects on hESC pluripotency
were observed at doses of the proteasome inhibitor
MG132 (0.5 μM) significantly lower than those typically
found in the literature (several μM) or in mice ES cells (20
μM) [23]. This observation is highly interesting in light of
the recent findings of the role of the proteasome in tran-
scription, especially in hESC. The 26S proteasome consists
of a 20S core proteolytic part, capped by a 19S regulatory
complex. Specificity of degradation of proteins is medi-
ated in part by poly-ubiquitination of the substrate bound
for destruction. Based on early work in yeast, the proteas-
ome is known to interact with chromatin and function at
multiple steps in transcription, both through proteolytic
and non-proteolytic activities [32]. Recently, Szutorisz et
al. reported that the 26S proteasome is assembled on
intergenic and intragenic regions in ES cells and act as a
transcriptional silencer by blocking non-specific transcrip-
tion initiation [23]. This mechanism involves the proteo-
lytic activity of the 20S core by degrading non-specific
preinitiation complexes, thereby preventing permissive
transcription and spreading of the modified chromatin.
Our results are consistent with this hypothesis, but final
answer on this issue will require further investigations.
This work has compared human MII oocytes and hESC to
somatic tissues gene expression profiles. One goal was to
provide new hints on the process of nucleus reprogram-
ming which takes place in vivo during early embryo devel-
opment or in vitro during SCNT, and may thus help to
improve the iPS technology. Indeed, since the seminal
work of the team of Shinya Yamanaka, numerous
improvement have been made, including the identifica-
tion of new genes able to replace some of the original ones
in the reprogramming cocktail, the use of small moleculesBMC Genomics 2009, 10:10 http://www.biomedcentral.com/1471-2164/10/10
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or the replacement of the retroviral vectors by adenovi-
ruses or plasmids [33-37]. A first observation is that
human mature oocytes do not express the pluripotency
core transcriptional genes POU5F1/OCT4, NANOG and
SOX2 [13], except POU5F1/OCT4 at low level (see Figure
1C and our Amazonia! on-line expression atlas, http://
amazonia.montp.inserm.fr). They neither express KLF4
nor  CMYC, which compose, with POU5F1/OCT4  and
SOX2, the four factors that can reprogram somatic cells by
virus-mediated overexpression [11]. From the six "repro-
gramming" factors described to date, only LIN28 was
found in the oocyte/hESC signature. However, POU5F1/
OCT4, NANOG, SOX2, KLF4, LIN28 and CMYC are all
expressed by hESC. Therefore, during early embryo devel-
opment, the expression of these genes is induced. Thus,
two different molecular pathways that can reprogram
adult somatic cells can be envisioned: (i) the process tak-
ing place in the oocyte cytoplasm, able to activate the core
transcriptional genes, or (ii) the overexpression of the core
transcriptional genes themselves together with adjuvant
genes, either by viral overexpression or by fusion with
cells already expressing these genes. It can be speculated
that the factors that lie upstream of the pluripotency core
transcriptional circuitry are expressed as mRNA in mature
MII oocytes and are still present at blastocyst stage from
which hESC are derived. Thus, the oocytes/hESC signature
likely includes these factors, and therefore this informa-
tion could be highly informative for cell reprogramming.
The signature contained numerous transcritption factors,
including many zinc finger such as ZNF84, several still
poorly annotated genes such as KLHL7,  MRS2, or the
Selenophosphate synthetase 1 (SEPHS1), displayed a
strong cell cycle signature, chromatin modification genes,
and also many actors of the proteasome pathway. All
these genes are candidate genes to improve the efficiency
of iPS generation, especially in the light of the recent
advances that uses non retroviral vectors but at the cost of
lower efficacy.
Conclusion
Human ESC are not only a very promising source of cells
for regenerative medicine, but are also a unique tool to
understand early embryo development that can not easily
be studied on live embryos because of ethical and techni-
cal limits. Our comparison of human mature oocytes and
hESC to a large collection of somatic samples helps to
understand the early embryo development and pluripo-
tency, and is therefore relevant for therapeutics, including
improvement of the pregnancy success rate in IVF and
regenerative medicine applications such as those involv-
ing cell reprogramming.
Methods
Transcriptome compendium
We built an expression compendium by combining
U133A and U133 Plus 2.0 (Affymetrix, Santa Clara, USA)
microarray data from 11 publications and from our labo-
ratory, totalizing 205 samples (Table 1; see Additional file
1) [18,38-47]. Data were analyzed with the GCOS 1.2
software (Affymetrix), using the default analysis settings
and global scaling as first normalization method, with a
trimmed mean target intensity value (TGT) of each array
arbitrarily set to 100. Data was floored at 50, i.e each value
below 50 was set to 50. In order to compare U133A and
U133 Plus 2.0 data, we further normalized the data with
a rank-based normalization method. This method,
"MetaNorm", orders the values of the 22 215 PS of the
Affymetrix U133A microarray and allocates a new value to
each PS according to its rank, using a unique signal value
template (Assou et al., manuscript in preparation). Sam-
ples are listed in Table 1 (see Additional file 1), along with
references, microarray design and, when available, GEO
(Gene Expression Omnibus) dataset number. The dataset
is available as Additional file 2 (signal and p-value) and
each PS can be individually accessed on our website http:/
/amazonia.montp.inserm.fr[20].
Data analysis and visualization
Principle component analysis (PCA) was performed using
ArrayAssist® software (Stratagene, La Jolla, CA, USA) to
provide a global view of how the various sample groups
were related. Hierarchical clustering was carried out with
CLUSTER and TREEVIEW software [48]. PCA and cluster-
ing were performed on 10,000 PS with the highest coeffi-
cient of variation (CV). Gene expression profiles were
identified using two-class Significance Analysis of Micro-
arrays (SAM) method [49]http://www-stat.stanford.edu/
~tibs/SAM/ which utilizes a Wilcoxon-test statistic and
sample-label permutations to evaluate statistical signifi-
cance. SAM analysis was applied after data filtering retain-
ing only PS with at least 2 samples with a "Present" call.
The False Discovery Rate (FDR), an estimate of the frac-
tion of selective genes, was kept below 5% in all statistical
analyses. Gene Ontology annotation analysis was carried
out using the Fatigo+ tool at the Babelomics website http:/
/babelomics.bioinfo.cipf.es[50]. Only annotations with a
false discovery rate-adjusted P-value below 0.05 were con-
sidered significant. To uncover functional biological net-
works, we imported gene expression signatures into the
Ingenuity Pathways Analysis (IPA) Software (Ingenuity
Systems, Redwood City, CA, USA). Comparison of the fre-
quency of zinc finger domain containing transcript
between the non-cell cycle oocytes/hESC signature and
the entire U133A microarray was carried out using a Pear-
son's Chi-squared test with Yates' continuity correction.
Human mature MII oocytes, fibroblasts and malignant cell 
lines transcriptome
Unfertilized MII oocytes were collected after informed
consent 44 hours post insemination or post microinjec-
tion by ICSI as previously published [18,44]. Briefly, Mll
oocytes were from couples referred to our center for cIVFBMC Genomics 2009, 10:10 http://www.biomedcentral.com/1471-2164/10/10
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(tubal infertility) or for ICSI (male infertility). Mature M2
oocytes were pooled: 16 oocytes for Oocyte_M2_16 sam-
ple, 21 for Oocyte_M2_21 and 24 for Oocyte_M2_24,
from 6, 8 and 8 patients respectively. Human foreskin
fibroblasts cell lines were described previously [20]. MCF7
and HEPG2 were from ATCC and cultured in DMEM
medium containing 10% fetal calf serum (FCS). Total
RNA was isolated using RNeasy mini kits (Qiagen, Court-
aboeuf, France) and quantified using a NanoDrop spec-
trophotometer (Thermo Fischer, Wilmington, Delaware,
USA). Total RNA (100 ng) was used to prepare twice
amplified labeled cRNA for hybridization to HG-U133
plus 2.0 GeneChip pangenomic oligonucleotide arrays
(Affymetrix, Santa Clara, CA, USA) as previously
described [18]. The 9 microarray data obtained in our lab
are accessible in US National Center for Biotechnology
Information, Gene Expression Omnibus (GEO) through
the provisional accession numbers GSE11450 (series),
and GSM288886, GSM288885, GSM288883,
GSM288882, GSM288880, GSM288878, GSM288877,
GSM288876, GSM288812 (samples).
hES cell culture
The HS181 hES cell line was imported from the Karolin-
ska Institute (Stockholm, Sweden). The HD83/D17/FE07-
135-L1 and HD90/D18/FE07-142-L1 hES cell lines were
derived in our laboratory from a normal embryo and an
embryo that carried an abnormal VHL gene according to
preimplantation genetic diagnostic, respectively (De Vos
et al. manuscript in preparation). Briefly, derivation of
HD83 and HD90 was carried out using mechanical disso-
ciation of the inner cell mass [51]. The culture medium
used for hESCs derivation and culture consisted of 80%
KO-DMEM, 20% knockout SR, 2 mM L-glutamine, 1%
nonessential amino acids, 0.5 mM β-mercaptoethanol
(all from Gibco Invitrogen, Cergy-Pontoise, France) and
10 ng/mL of bFGF (Abcys, Paris, France). Passaging was
performed mechanically by cutting the colony using a #15
scalpel under the microscope. Human foreskin fibroblasts
(HFF), mitotically inactivated using irradiation (40 Gy),
were used as feeder cells. HFF cells were cultured in 85%
DMEM, 15% FBS. All hESC expressed POU5F1/OCT4,
NANOG and TRA-1-60, and were able to differentiate into
embryoid bodies that expressed differentiation markers.
For proteasome inhibition experiments, hESC were incu-
bated 40 h with various concentration of MG132 (Sigma),
with medium renewal at 24 h.
Production of hES-derived fibroblasts
Briefly, hES cells were mechanically isolated and plated
on laminin precoated 6-wells culture dishes (Becton Dick-
inson, San Jose, CA, USA) in hESC culture medium
renewed every day. After 5 days, bFGF was removed, and
after three additional days, medium was switched to HFF
medium. In these conditions, hES cells differentiated into
flattened cells with elongated nucleus and branching
pseudopodia forming hESC-derived fibroblasts (hES-dF).
The hES-dF were then mechanically isolated and trans-
ferred to feeder free 6-wells culture dishes. Subsequent
passages were carried out using 0.05% trypsin- EDTA (Inv-
itrogen) every 6 days and cultures upscaled into T75
flasks.
RT-PCR and quantitative PCR (QRT-PCR)
RT-PCR was carried out on total RNA isolated from hESCs
grown in the absence or presence of increasing concentra-
tion of MG132. PCR conditions and sequence for each
primer are shown in Table 3. PCR products were separated
on a 1% agarose gel. Expression of the housekeeping gene
GAPDH was used to normalise PCR reactions. For QRT-
PCR, approximately 1 μg of linear-amplified, biotin-
labelled cDNA was mixed with Assays-on-Demand prim-
ers and probes and TaqMan Universal Master Mix accord-
ing to the manufacturer's instructions (Applied
Biosystems, Courtaboeuf, France). Real-time QRT-PCR
was performed using the ABI Prism 7000 sequence detec-
tion system (Applied Biosystems) and normalized to
GAPDH for each sample using the following formula in
which Ct is cycle threshold: 100/2ΔΔCt, where ΔΔCt = ΔCt
unknown -ΔCt positive control.
Table 3: Primer sequences and conditions used for RT-PCR
Gene Primer sequences (Forward, Reverse) Cycles MgCl2 (mM) Annealing Tm (°C) Product size (bp)
NANOG F: CAAAGGCAAACAACCCACTT
R: CTGGATGTTCTGG GTCTGGT
30 1.5 62 426
POU5F1/OCT4 F: GACAACAATGAGAACCTTCA
R: TTCTGGCGCCGGTTACAGAA
30 1.5 62 218
SOX2 F: ATGGACAGTTACGCGCACAT
R: GACTTGACCACCGAACCCAT
30 1.5 62 268
GAPDH F: AGCCACATCGCTCAGACACC
R: GTACTCAGCGGCCAGCATCG
30 1.5 62 238BMC Genomics 2009, 10:10 http://www.biomedcentral.com/1471-2164/10/10
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Immunofluorescence and cytometry flow
Cells were fixed with PBS containing 4% paraformalde-
hyde for 20 minutes at room temperature and blocked
with PBS containing 5% normal donkey serum for 30
minutes at room temperature. After blocking, cells were
incubated with the appropriate primary antibody against
POU5F1/OCT4 (sc-9081, Santa Cruz Biotechnology,
Santa Cruz, CA; 1:300) or against proline 4-hybroxylase
(P4H) (Dako, Trappes, France; 1:50) for 1 hour at room
temperature. Cells were washed three times in PBS and
incubated for 1 hour at room temperature with Alexa
Fluor®  488 donkey anti-Rabbit (A-11034; Molecular
Probes; 1:1000) and Alexa Fluor® 568 goat anti-mouse
antibody (A11019, Invitrogen; 1:400) secondary antibod-
ies for POU5F1/OCT4 and P4H respectively. Hoechst
staining was added to first wash (Sigma, 5 μg/ml).
For flow cytometry, cells were harvested by treatment with
0.05% trypsin- EDTA (Invitrogen) and were resuspended
in culture media. Cell aliquots were incubated on ice with
anti-CD13 MAb conjugated to phycoerythrin (PE)
(A07762, Beckman-Coulter, 1:50), anti-CD44 MAb con-
jugated to fluorescein isothiocyanate (FITC) (clone J-173,
Immunotech; 1:50) and Tra-1-60 (90232, Chemicon) or
conjugated isotypic controls. Flow cytometry was per-
formed on a fluorescence-activated cell sorter (FACS Scan,
Becton Dickinson), and data were analyzed with the Cel-
lquest software (Becton Dickinson).
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